Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1524149rdf:typepubmed:Citationlld:pubmed
pubmed-article:1524149lifeskim:mentionsumls-concept:C0019159lld:lifeskim
pubmed-article:1524149lifeskim:mentionsumls-concept:C0035647lld:lifeskim
pubmed-article:1524149lifeskim:mentionsumls-concept:C1456649lld:lifeskim
pubmed-article:1524149lifeskim:mentionsumls-concept:C1440044lld:lifeskim
pubmed-article:1524149lifeskim:mentionsumls-concept:C2607850lld:lifeskim
pubmed-article:1524149lifeskim:mentionsumls-concept:C0037640lld:lifeskim
pubmed-article:1524149lifeskim:mentionsumls-concept:C0348080lld:lifeskim
pubmed-article:1524149pubmed:issue3lld:pubmed
pubmed-article:1524149pubmed:dateCreated1992-10-15lld:pubmed
pubmed-article:1524149pubmed:abstractTextThe prevalence of serologic markers for hepatitis A, B, and C was investigated in children from two residential institutions in Somalia. Among 596 individuals at one residence (Shebeli), the prevalences were 96% for antibody to hepatitis A virus (anti-HAV), 75% for total hepatitis B virus (HBV) markers, 16% for hepatitis B surface antigen (HBsAg), and 1.5% for antibody to hepatitis C virus (anti-HCV). Corresponding figures for the 76 individuals at a smaller residence (Societe Organisation Sociale, SOS) were 59%, 20%, 3.9%, and 0%, respectively. At Shebeli, the HBsAg carrier rates in the 1-10-year-old age group was 28% for boys and 16% for girls. These rates were significantly higher than in the older children (16% and 7.4% for boys and girls, respectively). Fifty-eight percent of the HBsAg carriers were positive for hepatitis B e antigen. Total HBV markers were significantly more frequent in girls from Shebeli, when their duration of residence was longer than five years (89% versus 63%). The duration of stay did not influence the prevalences of HBsAg, HAV, or HCV antibodies. A followup study of children initially seronegative for HBV markers was carried out after two years. For children at Shebeli 1-10 years old, the annual seroconversion rates to HBV markers (95% confidence interval) was 60.5% (42.7-77.0%). The corresponding rate for children at SOS was 10.2% (5.2-17.5%). The differences between the two institutions in the prevalence of serologic markers for hepatitis A and B, and in the annual seroconversion rate to HBV markers reflected different rates of horizontal transmission.(ABSTRACT TRUNCATED AT 250 WORDS)lld:pubmed
pubmed-article:1524149pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1524149pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1524149pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1524149pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1524149pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1524149pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1524149pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1524149pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1524149pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1524149pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1524149pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1524149pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1524149pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1524149pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1524149pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1524149pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1524149pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1524149pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1524149pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1524149pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1524149pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1524149pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1524149pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1524149pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1524149pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1524149pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1524149pubmed:keywordhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1524149pubmed:languageenglld:pubmed
pubmed-article:1524149pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1524149pubmed:citationSubsetAIMlld:pubmed
pubmed-article:1524149pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1524149pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1524149pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1524149pubmed:statusMEDLINElld:pubmed
pubmed-article:1524149pubmed:monthSeplld:pubmed
pubmed-article:1524149pubmed:issn0002-9637lld:pubmed
pubmed-article:1524149pubmed:authorpubmed-author:NilssonLLlld:pubmed
pubmed-article:1524149pubmed:authorpubmed-author:MagniusLLlld:pubmed
pubmed-article:1524149pubmed:authorpubmed-author:Bie?MMlld:pubmed
pubmed-article:1524149pubmed:authorpubmed-author:AdenCClld:pubmed
pubmed-article:1524149pubmed:authorpubmed-author:NorderHHlld:pubmed
pubmed-article:1524149pubmed:authorpubmed-author:IssaEElld:pubmed
pubmed-article:1524149pubmed:authorpubmed-author:MohamudOOlld:pubmed
pubmed-article:1524149pubmed:issnTypePrintlld:pubmed
pubmed-article:1524149pubmed:volume47lld:pubmed
pubmed-article:1524149pubmed:ownerNLMlld:pubmed
pubmed-article:1524149pubmed:authorsCompleteYlld:pubmed
pubmed-article:1524149pubmed:pagination357-64lld:pubmed
pubmed-article:1524149pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:1524149pubmed:meshHeadingpubmed-meshheading:1524149-...lld:pubmed
pubmed-article:1524149pubmed:meshHeadingpubmed-meshheading:1524149-...lld:pubmed
pubmed-article:1524149pubmed:meshHeadingpubmed-meshheading:1524149-...lld:pubmed
pubmed-article:1524149pubmed:meshHeadingpubmed-meshheading:1524149-...lld:pubmed
pubmed-article:1524149pubmed:meshHeadingpubmed-meshheading:1524149-...lld:pubmed
pubmed-article:1524149pubmed:meshHeadingpubmed-meshheading:1524149-...lld:pubmed
pubmed-article:1524149pubmed:meshHeadingpubmed-meshheading:1524149-...lld:pubmed
pubmed-article:1524149pubmed:meshHeadingpubmed-meshheading:1524149-...lld:pubmed
pubmed-article:1524149pubmed:meshHeadingpubmed-meshheading:1524149-...lld:pubmed
pubmed-article:1524149pubmed:meshHeadingpubmed-meshheading:1524149-...lld:pubmed
pubmed-article:1524149pubmed:meshHeadingpubmed-meshheading:1524149-...lld:pubmed
pubmed-article:1524149pubmed:meshHeadingpubmed-meshheading:1524149-...lld:pubmed
pubmed-article:1524149pubmed:meshHeadingpubmed-meshheading:1524149-...lld:pubmed
pubmed-article:1524149pubmed:meshHeadingpubmed-meshheading:1524149-...lld:pubmed
pubmed-article:1524149pubmed:meshHeadingpubmed-meshheading:1524149-...lld:pubmed
pubmed-article:1524149pubmed:meshHeadingpubmed-meshheading:1524149-...lld:pubmed
pubmed-article:1524149pubmed:meshHeadingpubmed-meshheading:1524149-...lld:pubmed
pubmed-article:1524149pubmed:meshHeadingpubmed-meshheading:1524149-...lld:pubmed
pubmed-article:1524149pubmed:meshHeadingpubmed-meshheading:1524149-...lld:pubmed
pubmed-article:1524149pubmed:meshHeadingpubmed-meshheading:1524149-...lld:pubmed
pubmed-article:1524149pubmed:meshHeadingpubmed-meshheading:1524149-...lld:pubmed
pubmed-article:1524149pubmed:meshHeadingpubmed-meshheading:1524149-...lld:pubmed
pubmed-article:1524149pubmed:year1992lld:pubmed
pubmed-article:1524149pubmed:articleTitleThe risk for hepatitis A, B, and C at two institutions for children in Somalia with different socioeconomic conditions.lld:pubmed
pubmed-article:1524149pubmed:affiliationDepartment of Medicine, Faculty of Medicine, Mogadishu, Somalia.lld:pubmed
pubmed-article:1524149pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1524149pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed